High Burden of Readmissions After Major Surgery Leads to Poorer Outcomes, Higher Costs
the Cancer Therapy Advisor take:
The high burden of readmissions after major cancer surgery leads to poorer patient outcomes and higher costs, according to a recent study published in the Journal of Clinical Oncology.
Karyn B. Stitzenberg, MD, and fellow researchers at the University of North Carolina examined SEER-Medicare patient data from 2001 to 2007 of patients with cancer of the bladder, pancreas, or esophagus in. They calculated readmission rates using Kaplan-Meier functions. Only patients who underwent extirpative surgery were included.
Based on tumor type, readmission ranged from 13 to 29 percent for 30-day rates and 23 to 43 percent for 90-day rates. The researchers found that long-term survival as well as costs of care were worse among patients who were readmitted.
Predictors of readmission included discharge to somewhere other than home, longer length of stay, comorbidities , and higher stage of diagnosis. Longer travel distance to hospital was also a factor, with those patients more likely to be readmitted to a hospital other than the index hospital.
“Interventions targeted at higher risk individuals could potentially decrease the population burden of readmissions after major cancer surgery,” the authors concluded.
The high burden of readmissions after major cancer surgery leads to poorer patient outcomes and higher costs.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Patient-Reported Outcomes in Oncology Expected to Make Regulatory Waves
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- FDA Provides Update on Breast Implant-Associated Anaplastic Large Cell Lymphoma
- Q&A With Mark B. Gerstein, PhD, on Diagnostic Genomic vs Exomic Sequencing
- Immune Signature for Renal Cell Papillary Carcinoma Predicts Outcome
- Nivolumab-Ipilimumab Survival Benefit in Advanced RCC Confirmed
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Adding Chemotherapy to Radiation Post-Radical Cystectomy Improves Survival in Urothelial Carcinoma
- Radiation, Chemotherapy Not Beneficial in Localized Upper Tract Urothelial Carcinoma
- Radical Cystectomy Superior to Trimodal Therapy for Muscle-Invasive Bladder Cancer